Current active clinical trials June 2023:
ACHEIVE: Aldosterone bloCkade for Helath Improvement EValuation in End-stage Renal Disease. Sponsor: Population Health Research Institute Canada
ACTION3: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB). Sponsor: Dimerix Bioscience Pty Ltd
AFFINITY: A Phase 2, Open-Label, Basket Study of Atrasentan in Patients with Proteinuric Glomerular Diseases. Sponsor: Chinook USA
ALIGN: A Phase III, double-blind, placebo-controlled study to compare efficacy and safety of Atrasentan to placebo in patients with IgA nephropathy. Sponsor: Chinook USA
APPLAUSE-IgAN: A multi-center, randomized, double-blind, placebocontrolled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients Sponsor: Novartis Pharmaceuticals Australia Pty Limited
ARTEMIS-IGAN: A randomised, double-blind, placebo-controlled, phase III study of the safety and efficacy of OMS721 in patients with IgA Nephropathy. Sponsor: Omeros Corporation USA
BEAT Calci: Better Evidence And Translation for Calciphylaxis Sponsor: University of Sydney
FIND CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease Sponsor: Bayer Healthcare Pharmaceuticals Inc., USA
GLOBAL KIDNEY PATIENT TRIALS NETWORK: A prospective observational cohort study of incident and prevalent patients diagnosed with a kidney disease. Sponsor: The George Institute Australia
GOAL: Comprehensive geriatric assessment for frail older people with Chronic Kidney Disease to increase attainment of patient-identified goals - A cluster randomised controlled trial. Sponsor: Australasian Kidney Trials Network
KICK 2: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12- Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Severe Pruritus and Not on Dialysis with an Up to 52-Week Long Term Extension Sponsor: ICON Clinical Research Pty Limited
Nef-301 OLE: An Open-Label Extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgA Nephropathy who have completed study Nef-301 Sponsor: Calliditas Therapeutics AB Sweden
ORIGIN: A Phase IIB randomized, double-blinded, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of Atacicept in subjects with IgA Nephropathy Sponsor: Vera Therapeutics, Inc South San Francisco
PHOENYCS: A Phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of Dapirolizumab Pegol in patients with moderate to severe Systemic Lupus Erythematosis. Sponsor: UCB Biopharma SRL Belgium.
POSIBIL6ESKD: A Phase 2b / 3, Multicenter, Randomized, Double-blind,Placebocontrolled,Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis Sponsor: CSL Innovation Pty Ltd
SER150: A Phase 2/3, double-blind, randomised, placebo controlled, parallel groups study evaluating the safety and efficacy of SER150 in patients with well controlled type 2 diabetic patients with Diabetic Kidney Disease and macroalbuminuria. Sponsor: Serodus (AUS) Pty Ltd
TRACK: Randomised, double-blind, placebo-controlled trial in the treatment of CVD with low dose Rivaroxaban in Advanced CKD. Sponsor: The George Institute Australia
VC2: Victorian COVID-19 Vaccines Collection Sponsor:The University of Melbourne
VISIONARY: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
We also lead project interventions for chronic disease detection and management in the primary care setting including novel technology solutions. These include:
Chronic Disease IMPACT: Chronic Disease IMPACT (Chronic Disease early detection and Improved Management in PrimAry Care ProjecT), in collaboration with University of Melbourne and Victoria University
Future Health Today in collaboration with the University of Melbourne
More information
For more information regarding the Western Health Renal Research Unit including if you would like to find out about collaborating or participating in any of our trials please contact:
A/Prof Craig Nelson, Head of Renal Services
Sunshine Hospital
176 Furlong Rd
St Albans 3021
Telephone 61 8345 1333
Email: [email protected]
Prof Eugenia Pedagogos, Head of Renal Clinical Trials
Sunshine Hospital
176 Furlong Rd
St Albans 3021
Telephone +61 8345 1333
Email: [email protected]
Shannon Kokoszka, Renal Research Unit Team Leader
Sunshine Hospital
176 Furlong Rd
St Albans 3021
Telephone +61 8395 8058
Email: [email protected]
